TRIGLYCERIDES LIQUID, 1 x 100 mL + ST

    992330



    To access the documentation you must be registered

    Register


    Conformité européenne In vitro diagnostic product

    For in vitro determination of Triglycerides in serum plasma.

    State Liquid
    Storage temp. +2 / +8º C
    Technique GPO method

    PRINCIPLE

    Triglycerides present in the sample are enzymatically hydrolysed by the action of lipases leading to glycerol and fatty acids. In presence of glycerol kinase (GK), the ATP phosphorylates glycerol to give glycerol-3-phosphate and the corresponding ADP. By glycerophosphate oxidase (GPO), glycerol -3 - phosphate is oxidized to dihydroxyacetone phosphate and hydrogen peroxide. In the last stage, with the peroxidase as a catalyst, hydrogen peroxide reacts with 4-aminoantipyrine and 4-chlorophenol to give quinoneimine. The intensity of the red colour is proportional to the amount of triglycerides present in the sample.

    DIAGNOSTIC USE

    The increased blood triglyceride level is a risk factor in the development of coronary heart disease. About 50% of the lipids of atheromatous lesions occurring in the coronary arteries are triglycerides, making it possible to relate to the pathogenesis of coronary arteriosclerosis. The determination of triglycerides allows assessing the early risk of developing coronary atherosclerosis. The TGL may be increased by chylomicronemia (Fredrickson types I and V), type IV hypertriglyceridemia, diabetes mellitus, insulin resistance, obesity, hypothyroidism, pancreatitis, glycogen storage disease, nephrotic syndrome, hypertriglyceridemia sensitive to carbohydrates, Tangiers disease, von Gierke's disease, pernicious anemia, acute pancreatitis, Downs syndrome, biliary cirrhosis, septicemia. A single test result cannot be used to make a clinical diagnosis. The results are to be evaluated in the context of all clinical and laboratory data obtained.